Eltrombopag

Generic Name
Eltrombopag
Brand Names
Promacta, Revolade
Drug Type
Small Molecule
Chemical Formula
C25H22N4O4
CAS Number
496775-61-2
Unique Ingredient Identifier
S56D65XJ9G
Background

Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also bee...

Indication

Thrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow. In this, they differ from the previously discussed agents that act by attempting to curtail platelet destruction.

Associated Conditions
Chronic immune thrombocytopenia, Severe Aplastic Anemia (SAA), Thrombocytopenia
Associated Therapies
First-line Therapy
Clinical Trials
Related News

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

First Posted Date
2019-02-18
Last Posted Date
2020-01-10
Lead Sponsor
Wei Zhao
Target Recruit Count
1500
Registration Number
NCT03844360
Locations
🇨🇳

State Key Laboratory of Experimental Haematology, Department of Paediatric Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tanjin, Tianjin, China

Safety and Efficacy of Eltrombopag Plus Pulsed Dexamethasone for Subjects With Idiopathic Thrombocytopenic Purpura

Phase 2
Completed
Conditions
Immune Thrombocytopenia
Interventions
Drug: Eltrombopag
First Posted Date
2019-02-05
Last Posted Date
2024-02-28
Lead Sponsor
Humanity & Health Medical Group Limited
Target Recruit Count
53
Registration Number
NCT03830749
Locations
🇭🇰

Humanity & Health Research Centre, Hong Kong, Hong Kong SAR, Hong Kong

Efficacy and Safety of rhTPO and Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP)

First Posted Date
2018-12-11
Last Posted Date
2019-11-15
Lead Sponsor
Wuhan Union Hospital, China
Target Recruit Count
96
Registration Number
NCT03771378
Locations
🇨🇳

Zhou Yiming, Wuhan, Hubei, China

Study of Efficacy and Safety of Eltrombopag in Patients With Poor Graft Function

Phase 2
Terminated
Conditions
Poor Graft Function
Interventions
Drug: Eltrombopag
First Posted Date
2018-10-24
Last Posted Date
2024-02-29
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
10
Registration Number
NCT03718533
Locations
🇪🇸

Novartis Investigative Site, Barcelona, Spain

Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML

First Posted Date
2018-10-09
Last Posted Date
2018-10-09
Lead Sponsor
Nanfang Hospital, Southern Medical University
Target Recruit Count
220
Registration Number
NCT03701217
Locations
🇨🇳

Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

to Evaluate the Efficacy and Safety of Eltrombopag for Immune Thrombocytopenia With Chronic HBV Infection

First Posted Date
2018-09-10
Last Posted Date
2023-08-14
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
48
Registration Number
NCT03664518
Locations
🇨🇳

Ethics Committee of Blood disease hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China

Perioperative Eltrombopag in Patients With Inherited Thrombocytopenia

Phase 2
Completed
Conditions
Thrombocytopenia
Interventions
Drug: Eltrombopag
First Posted Date
2018-08-20
Last Posted Date
2024-08-27
Lead Sponsor
University Hospital, Toulouse
Target Recruit Count
13
Registration Number
NCT03638817
Locations
🇫🇷

Angers Hospital, Angers, France

🇫🇷

Bordeaux Hospital, Bordeaux, France

🇫🇷

Kremlin Bicetre Hospital, Paris, France

and more 22 locations

Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy

Phase 2
Active, not recruiting
Conditions
Acute Myeloid Leukemia
Interventions
Drug: Placebo
Drug: Eltrombopag
First Posted Date
2018-07-27
Last Posted Date
2024-10-29
Lead Sponsor
French Innovative Leukemia Organisation
Target Recruit Count
110
Registration Number
NCT03603795
Locations
🇫🇷

Hôpital Saint-Eloi - Hématologie Clinique, Montpellier, France

🇫🇷

HOPITAL E. MULLER - Hématologie, Mulhouse, France

🇫🇷

CH de la Côte Basque - Hématologie, Bayonne, France

and more 12 locations

A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP

Phase 2
Completed
Conditions
Immune Thrombocytopenic Purpura (ITP)
Interventions
Drug: eltrombopag
First Posted Date
2018-05-15
Last Posted Date
2024-06-20
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
105
Registration Number
NCT03524612
Locations
🇺🇸

Hematology Oncology Association of Rockland Drug Shipment, Nyack, New York, United States

🇺🇸

Case Western Reserve SC - 2, Cleveland, Ohio, United States

🇬🇧

Novartis Investigative Site, London, United Kingdom

Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT

First Posted Date
2018-05-03
Last Posted Date
2022-07-27
Lead Sponsor
Shenzhen Second People's Hospital
Target Recruit Count
98
Registration Number
NCT03515096
Locations
🇨🇳

Shenzhen Second People's Hospital, Shenzhen, Guangdong, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy